



Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

April 7, 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 7, 2026-- [Enanta Pharmaceuticals, Inc.](#) (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of RSV, have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany.

The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom resolution and a lower hospitalization rate, and featuring new findings demonstrating strong exposure multiples over the EC₉₀. The second oral presentation will highlight new data confirming zelicapavir's high clinical and functional barrier against antiviral resistance, generated from the Phase 2 study in pediatric patients, which was announced in September 2024.

Details of the presentations are as follows:

Presentation Title: Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV

Abstract Number: 3963

Date: April 18, 2026

Time: 8:30 a.m. CEST / 2:30 a.m. EDT

Location: Hall A1-3

Session Type: 2-hour Oral Session

Session Title: Three viruses, one winter: what we miss, what we treat, what comes next

Presenter: Scott T. Rottinghaus, M.D.

ePoster Title: Zelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial

Abstract Number: 5360

Date: April 18, 2026

Time: 8:30 a.m. CEST / 2:30 a.m. EDT

Location: Arena 2

ePoster Number: E0043

Session Type: ePoster Flash Session

Session Title: Old viruses, new weapons: emerging antiviral therapies from bench to bedside

Presenter: John P. DeVincenzo, M.D.

Further information about ESCMID Global 2026 can be found [here](#). Presentations will be available on the Company's website [here](#) following each presentation.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit www.enanta.com for more information.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260407155688/en/): <https://www.businesswire.com/news/home/20260407155688/en/>

Media and Investors:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.